Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 April 2024
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 March 2022
Testing strategies for Lynch syndrome in people with endometrial cancer (DG42)Product type:GuidanceProgramme:Diagnostics guidancePublished: 28 October 2020
Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer (IPG356)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 September 2010
Laparoscopic techniques for hysterectomy (IPG239)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 November 2007